The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy (CRUKE/11/061).
Rosalie A. Fisher
No relevant relationships to disclose
Andrew Rowan
No relevant relationships to disclose
Mark Stares
No relevant relationships to disclose
Mark F Webster-Smith
No relevant relationships to disclose
Rebecca Lewis
No relevant relationships to disclose
Lucy S Kilburn
No relevant relationships to disclose
David Nicol
No relevant relationships to disclose
Grant Stewart
No relevant relationships to disclose
Agnieszka Michael
Honoraria - Pfizer
Naveen Vasudev
No relevant relationships to disclose
Steve Hazell
No relevant relationships to disclose
Samra Turaljic
No relevant relationships to disclose
Lisa M. Pickering
Consultant or Advisory Role - Pfizer
Martin Eric Gore
No relevant relationships to disclose
Claire Snowdon
No relevant relationships to disclose
Judith M. Bliss
Honoraria - Pfizer
Research Funding - Pfizer
Charles Swanton
Research Funding - Pfizer
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer